Published in Br J Haematol on July 30, 2012
Epstein-Barr virus and Burkitt lymphoma. Chin J Cancer (2014) 1.02
Outcomes for paediatric Burkitt lymphoma treated with anthracycline-based therapy in Malawi. Br J Haematol (2016) 0.85
Plasma Epstein-Barr virus DNA for pediatric Burkitt lymphoma diagnosis, prognosis and response assessment in Malawi. Int J Cancer (2017) 0.78
Burkitt lymphoma in adolescents and young adults: management challenges. Adolesc Health Med Ther (2016) 0.75
Differential IgM expression distinguishes two types of pediatric Burkitt lymphoma in mouse and human. Oncotarget (2016) 0.75
Beyond Endemic Burkitt Lymphoma: Navigating Challenges of Differentiating Childhood Lymphoma Diagnoses Amid Limitations in Pathology Resources in Lilongwe, Malawi. Glob Pediatr Health (2017) 0.75
A sarcoma involving the jaws in African children. Br J Surg (1958) 10.60
Classification, staging and end results of treatment of childhood non-Hodgkin's lymphomas: dissimilarities from lymphomas in adults. Semin Oncol (1980) 2.64
AN EPIDEMIOLOGIC APPROACH TO THE LYMPHOMAS OF AFRICAN CHILDREN AND BURKITT'S SACROMA OF THE JAWS. Perspect Biol Med (1964) 2.56
Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol (1996) 2.05
Long-term remissions following one and two-dose chemotherapy for African lymphoma. Cancer (1967) 1.81
Treatment of acute lymphoblastic leukaemia in countries with limited resources; lessons from use of a single protocol in India over a twenty year period [corrected]. Eur J Cancer (2005) 1.67
A children's cancer dependent on climatic factors. Nature (1962) 1.61
Lymphomas in sub-Saharan Africa--what can we learn and how can we help in improving diagnosis, managing patients and fostering translational research? Br J Haematol (2011) 1.39
THE AFRICAN LYMPHOMA (BURKITT TUMOUR): SURVIVALS EXCEEDING TWO YEARS. Br J Cancer (1965) 1.33
Long-term survival of patients with Burkitt's lymphoma: an assessment of treatment and other factors which may relate to survival. Cancer Res (1967) 1.31
Spatial distribution of Burkitt's lymphoma in Kenya and association with malaria risk. Trop Med Int Health (2007) 1.29
Prognostic factors in Burkitt's lymphoma: importance of total tumor burden. Cancer (1980) 1.29
African Burkitt's lymphoma. History, biology, clinical features, and treatment. Am J Pediatr Hematol Oncol (1991) 1.16
Surgical reduction of tumour bulk in management of abdominal Burkitt's lymphoma. Br Med J (1974) 1.13
Burkitt's lymphoma in the Mengo Districts of Uganda: epidemiologic features and their relationship to malaria. J Natl Cancer Inst (1976) 1.10
Cure of Burkitt's lymphoma. Ten-year follow-up of 157 Ugandan patients. Lancet (1979) 1.07
Relapse patterns in Burkitt's lymphoma. Cancer Res (1972) 1.05
Long term survival of children with Burkitt lymphoma in Malawi after cyclophosphamide monotherapy. Med Pediatr Oncol (2003) 1.03
Long-term experience with Burkitt's lymphoma in Uganda. Int J Cancer (1980) 1.03
Diagnosis of Burkitt lymphoma using an algorithmic approach--applicable in both resource-poor and resource-rich countries. Br J Haematol (2011) 1.02
Chemotherapy of Burkitt's lymphoma. Cancer (1972) 1.02
Malawi pilot study of Burkitt lymphoma treatment. Med Pediatr Oncol (2003) 1.01
Socioeconomic constraints to effective management of Burkitt's lymphoma in south-eastern Nigeria. Trop Med Int Health (2005) 1.00
Endemic Burkitt lymphoma: a 28-day treatment schedule with cyclophosphamide and intrathecal methotrexate. Ann Trop Paediatr (2009) 0.98
Lessons from clinical trials in African Burkitt lymphoma. Curr Opin Oncol (2009) 0.96
Burkitt lymphoma in Papua, New Guinea. Br J Cancer (1967) 0.95
The Cameroon 2008 Burkitt lymphoma protocol: improved event-free survival with treatment adapted to disease stage and the response to induction therapy. Pediatr Hematol Oncol (2012) 0.92
Cyclophosphamide monotherapy in children with Burkitt lymphoma: a study from the French-African Pediatric Oncology Group (GFAOP). Pediatr Blood Cancer (2011) 0.91
Intrathecal chemotherapy in Burkitt's lymphoma. Br Med J (1971) 0.89
Towards curative therapy in burkitt lymphoma: the role of early african studies in demonstrating the value of combination therapy and CNS prophylaxis. Adv Hematol (2012) 0.87
Preliminary report of an intensified, short duration chemotherapy protocol for the treatment of pediatric non-Hodgkin's lymphoma in India. Ann Oncol (1997) 0.87
The use of ultrasound in endemic Burkitt lymphoma in Cameroon. Pediatr Blood Cancer (2011) 0.85
Additional chemotherapy agents improve treatment outcome for children and adults with advanced B-cell lymphomas. Semin Oncol (1998) 0.83
Treatment of Burkitt's lymphoma: randomized clinical trial of single-agent versus combination chemotherapy. Int J Cancer (1976) 0.83
CNS involvement in small noncleaved-cell lymphoma: is CNS disease per se a poor prognostic sign? J Clin Oncol (1991) 0.81
Cerebrospinal irradiation of Burkitt's lymphoma. Failure in preventing central nervous system relapse. Acta Radiol Ther Phys Biol (1977) 0.78
Results of treatment with CMA, a low intermediate regimen, in endemic Burkitt lymphomas in sub-Saharian Africa: experience of Côte d'Ivoire. Int J Hematol (2010) 0.77
Prognostic significance of biochemical markers in African Burkitt's lymphoma. Clin Transl Oncol (2011) 0.77
Childhood non-Hodgkin's lymphoma in Egypt: preliminary results of treatment with a new ifosfamide-containing regimen. Cancer Chemother Pharmacol (1989) 0.76
Follicular lymphoma international prognostic index. Blood (2004) 7.20
Genetic heterogeneity of diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A (2013) 3.25
Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma. J Clin Oncol (2006) 2.82
Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251. J Immunol (2005) 2.72
Baseline status of paediatric oncology care in ten low-income or mid-income countries receiving My Child Matters support: a descriptive study. Lancet Oncol (2008) 2.49
Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol (2008) 2.32
The relationship between renal tumor size and metastases in patients with von Hippel-Lindau disease. J Urol (2004) 2.32
AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy. Blood (2006) 2.09
Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. Lancet Oncol (2011) 2.06
A simplified method for the rapid fluorometric assessment of antibody-dependent cell-mediated cytotoxicity. J Immunol Methods (2005) 2.03
Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer. Clin Cancer Res (2008) 1.95
Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines. J Immunol (2009) 1.93
Synergistic enhancement of CD8+ T cell-mediated tumor vaccine efficacy by an anti-transforming growth factor-beta monoclonal antibody. Clin Cancer Res (2009) 1.86
Smallpox vaccine safety is dependent on T cells and not B cells. J Infect Dis (2011) 1.86
Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting. J Virol (2004) 1.83
Immune activation driven by CTLA-4 blockade augments viral replication at mucosal sites in simian immunodeficiency virus infection. J Immunol (2008) 1.69
Vaccine-induced myeloid cell population dampens protective immunity to SIV. J Clin Invest (2014) 1.64
TLR3-specific double-stranded RNA oligonucleotide adjuvants induce dendritic cell cross-presentation, CTL responses, and antiviral protection. J Immunol (2011) 1.61
Treatment of B-cell lymphoma with LMB modified protocols in Africa--report of the French-African Pediatric Oncology Group (GFAOP). Pediatr Blood Cancer (2008) 1.59
Outcome and pathologic classification of children and adolescents with mediastinal large B-cell lymphoma treated with FAB/LMB96 mature B-NHL therapy. Blood (2012) 1.57
The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors. Mol Cancer Ther (2009) 1.57
Vaccine-induced CD8+ central memory T cells in protection from simian AIDS. J Immunol (2005) 1.54
Vaccination of macaques with long-standing SIVmac251 infection lowers the viral set point after cessation of antiretroviral therapy. J Immunol (2002) 1.52
DNA vaccines expressing different forms of simian immunodeficiency virus antigens decrease viremia upon SIVmac251 challenge. J Virol (2005) 1.52
Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. J Clin Oncol (2006) 1.45
CTLA-4 blockade decreases TGF-beta, IDO, and viral RNA expression in tissues of SIVmac251-infected macaques. Blood (2006) 1.45
Subunit recombinant vaccine protects against monkeypox. J Immunol (2006) 1.44
Estrogen receptor α and aromatase polymorphisms affect risk, prognosis, and therapeutic outcome in men with castration-resistant prostate cancer treated with docetaxel-based therapy. J Clin Endocrinol Metab (2010) 1.44
Genome-wide analysis of acute myeloid leukemia with normal karyotype reveals a unique pattern of homeobox gene expression distinct from those with translocation-mediated fusion events. Genes Chromosomes Cancer (2003) 1.43
Effect of raloxifene on mammographic density and breast magnetic resonance imaging in premenopausal women at increased risk for breast cancer. Cancer Epidemiol Biomarkers Prev (2008) 1.43
A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer. BJU Int (2008) 1.41
Gene expression analysis uncovers similarity and differences among Burkitt lymphoma subtypes. Blood (2011) 1.40
Lymphomas in sub-Saharan Africa--what can we learn and how can we help in improving diagnosis, managing patients and fostering translational research? Br J Haematol (2011) 1.39
Targeted genomic sequencing of pediatric Burkitt lymphoma identifies recurrent alterations in antiapoptotic and chromatin-remodeling genes. Blood (2012) 1.38
Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. J Clin Oncol (2010) 1.38
Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior. Blood (2009) 1.36
Castleman's disease and lymphoma: report of eight cases in HIV-negative patients and literature review. Am J Hematol (2002) 1.35
Expression of OATP family members in hormone-related cancers: potential markers of progression. PLoS One (2011) 1.32
Reduced protection from simian immunodeficiency virus SIVmac251 infection afforded by memory CD8+ T cells induced by vaccination during CD4+ T-cell deficiency. J Virol (2008) 1.31
Immunoglobulin gene analysis reveals 2 distinct cells of origin for EBV-positive and EBV-negative Burkitt lymphomas. Blood (2005) 1.30
Innate and adaptive immune correlates of vaccine and adjuvant-induced control of mucosal transmission of SIV in macaques. Proc Natl Acad Sci U S A (2010) 1.28
Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma. Blood (2012) 1.27
Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib. J Exp Clin Cancer Res (2010) 1.23
The chemopreventive agent N-(4-hydroxyphenyl)retinamide induces apoptosis through a mitochondrial pathway regulated by proteins from the Bcl-2 family. Oncogene (2003) 1.22
Evaluation of passively transferred, nonneutralizing antibody-dependent cellular cytotoxicity-mediating IgG in protection of neonatal rhesus macaques against oral SIVmac251 challenge. J Immunol (2006) 1.22
Variables affecting the quantitation of CD22 in neoplastic B cells. Cytometry B Clin Cytom (2010) 1.21
Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia. Clin Cancer Res (2012) 1.21
An adenovirus-based HIV subtype B prime/boost vaccine regimen elicits antibodies mediating broad antibody-dependent cellular cytotoxicity against non-subtype B HIV strains. J Acquir Immune Defic Syndr (2006) 1.21
Alteration of microRNAs regulated by c-Myc in Burkitt lymphoma. PLoS One (2010) 1.20
Characteristics of B-cell lymphomas in HIV/HCV-coinfected patients during the combined antiretroviral therapy era: an ANRS CO16 LYMPHOVIR cohort study. J Acquir Immune Defic Syndr (2013) 1.18
Clinical Features and Outcome in HIV-Associated Multicentric Castleman's Disease. J Clin Oncol (2011) 1.18
Interleukin-15 but not interleukin-7 abrogates vaccine-induced decrease in virus level in simian immunodeficiency virus mac251-infected macaques. J Immunol (2007) 1.18
Smallpox vaccine does not protect macaques with AIDS from a lethal monkeypox virus challenge. J Infect Dis (2005) 1.17
Vaccine-elicited SIV and HIV envelope-specific IgA and IgG memory B cells in rhesus macaque peripheral blood correlate with functional antibody responses and reduced viremia. Vaccine (2011) 1.16
B-cell differentiation in EBV-positive Burkitt lymphoma is impaired at posttranscriptional level by miRNA-altered expression. Int J Cancer (2010) 1.16
Modeling a safer smallpox vaccination regimen, for human immunodeficiency virus type 1-infected patients, in immunocompromised macaques. J Infect Dis (2003) 1.15
Clinical pharmacology and pharmacogenetics in a genomics era: the DMET platform. Pharmacogenomics (2010) 1.15
Protection afforded by an HIV vaccine candidate in macaques depends on the dose of SIVmac251 at challenge exposure. J Virol (2013) 1.12
The NFATc1 transcription factor is widely expressed in white cells and translocates from the cytoplasm to the nucleus in a subset of human lymphomas. Br J Haematol (2005) 1.12
New policies to address the global burden of childhood cancers. Lancet Oncol (2013) 1.12
TRIM5α does not affect simian immunodeficiency virus SIV(mac251) replication in vaccinated or unvaccinated Indian rhesus macaques following intrarectal challenge exposure. J Virol (2011) 1.11
CDK9/CYCLIN T1 expression during normal lymphoid differentiation and malignant transformation. J Pathol (2004) 1.11
Infant-feeding pattern of HIV-positive women in a prevention of mother-to-child transmission (PMTCT) programme. AIDS Care (2010) 1.10
Minimal residual disease detection in hairy cell leukemia. Comparison of flow cytometric immunophenotyping with clonal analysis using consensus primer polymerase chain reaction for the heavy chain gene. Am J Clin Pathol (2003) 1.09
Human T-cell leukemia virus type 1 p8 protein increases cellular conduits and virus transmission. Proc Natl Acad Sci U S A (2010) 1.09
Association of killer cell immunoglobulin-like receptor genes with Hodgkin's lymphoma in a familial study. PLoS One (2007) 1.09
Diagnostic telepathology: long-term experience of a single institution. Virchows Arch (2004) 1.08
PK11195 potently sensitizes to apoptosis induction independently from the peripheral benzodiazepin receptor. Oncogene (2005) 1.07
Pediatric diffuse large B-cell lymphoma demonstrates a high proliferation index, frequent c-Myc protein expression, and a high incidence of germinal center subtype: Report of the French-American-British (FAB) international study group. Pediatr Blood Cancer (2008) 1.07
The mutator pathway is a feature of immunodeficiency-related lymphomas. Proc Natl Acad Sci U S A (2004) 1.04
Positive correlation between Epstein-Barr virus viral load and anti-viral capsid immunoglobulin G titers determined for Hodgkin's lymphoma patients and their relatives. J Clin Microbiol (2006) 1.03
Diagnosis of Burkitt lymphoma using an algorithmic approach--applicable in both resource-poor and resource-rich countries. Br J Haematol (2011) 1.02
Rationale for consolidation to improve progression-free survival in patients with non-Hodgkin's lymphoma: a review of the evidence. Oncologist (2009) 1.02
Delicate balance among three types of T cells in concurrent regulation of tumor immunity. Cancer Res (2013) 1.02